Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway [Seeking Alpha]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Seeking Alpha
Topline results are expected this November. PUL 2.0 (a skeletal muscle endpoint) remains the primary endpoint, with left ventricle ejection fraction being a key secondary endpoint. Regulatory uncertainty remains on the scenario of HOPE 3 meeting the cardiac endpoint, but failing the primary skeletal muscle endpoint. Prior data are not without significant limitations and success is not guaranteed. HOPE 3 readout is a binary event with considerable risk. CAPR has a sufficient runway to a potential approval, assuming no more regulatory delays, with potential for significant non-dilutive funding from partner milestones and priority review voucher. JOSE LUIS CALVO MARTIN & JOSE ENRIQUE GARCIA-MAURIÑO MUZQUIZ/iStock via Getty Images Thesis overview Capricor Therapeutics ( NASDAQ: CAPR ) is developing deramiocel (previously known as CAP-1002), a cell-based exosome therapy for Duchenne Muscular Dystrophy (DMD). I recently covered CAPR following This article was written by Ana
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
- Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at Maxim Group.MarketBeat
- Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025GlobeNewswire
- Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at Roth Capital.MarketBeat
CAPR
Earnings
- 11/10/25 - In-Line
CAPR
Sec Filings
- 12/4/25 - Form 424B5
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- CAPR's page on the SEC website